Option chain shows key data for Hikma Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Hikma Pharmaceuticals.

Hikma Pharmaceuticals (OTC:HKMPY) Stock, Option Chain

HIKMA PHARM

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Biotech

Large Cap

News

Health Care

General

HKMPF

HKMPY

MCKPF

MNKTQ

TEVA

VTRS

Increase in production of Takeda&#39;s ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.

Shortage Relief: More Takeda&#39;s Vyvanse For ADHD On the Way As US Ramps Up Production

JAZZ

Legal

Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices

The FDA is actively seeking new suppliers to address the shortages of methotrexate, a widely used cancer drug in short supply since March. 

Methotrexate is an injected medication utilized to treat various cancers and autoimmune diseases like rheumatoid arthritis, as stated by the National Cancer Institute.

Drug Shortages in Focus: How FDA&#39;s Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape

HIKMA PHARMS PLC S/ADR by Hikma Pharmaceuticals plc.

Hikma Pharmaceuticals PLC

Barclays analyst Emily Field maintained a Hold rating on Hikma Pharmaceuticals (HIK – Research Report) today and set a price target of £20.00. The ...

Hikma Pharmaceuticals (HIK) Gets a Hold from Barclays

Citi analyst Peter Verdult assigned a Buy rating to Hikma Pharmaceuticals (HIK – Research Report) today and set a price target of £28.45. The compa...

Citi Issues a Buy Rating on Hikma Pharmaceuticals (HIK)

Hikma Pharmaceuticals PLC (HKMPF) Q2 2024 Pre-Recorded Presentation Transcript

Hikma Pharmaceuticals PLC (HKMPF) Q2 2024 Earnings Call Transcript

Analyst Christian Glennie of Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report), with a price target of p2,50...

Buy Rating Affirmed for Hikma Pharmaceuticals on Strong Performance and Growth Prospects

Hikma Pharmaceuticals (HIK – Research Report) received a Buy rating and a p2,400.00 price target from Berenberg Bank analyst Victoria Lambert yeste...

Positive Report for Hikma Pharmaceuticals (HIK) from Berenberg Bank

Analyst Christian Glennie from Stifel Nicolaus maintained a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the price targe...

Hikma Pharmaceuticals: Strategic Leadership and Expansion Drive a Compelling Buy Recommendation

Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the price targe...

Hikma Pharmaceuticals: Strategic Growth and Attractive Valuation Reinforce Buy Rating

In a report released today, Emily Field from Barclays maintained a Hold rating on Hikma Pharmaceuticals (HIK – Research Report), with a price targe...

Barclays Keeps Their Hold Rating on Hikma Pharmaceuticals (HIK)

Press Releases

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

Activ Surgical Announces Completion of First International Procedure Using Its ActivSight™ Intelligent Light

Small Cap

Hikma announces US launch of COMBOGESIC® IV

Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months

Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day

Comments

Hikma Pharmaceuticals

Hikma Pharmaceuticals (HKMPY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga